Sep 10, 2019
Nassim Usman, CEO, Catalyst Biosciences discusses the problem of Hemophilia, a rare and debilitating disease in which patients have a genetic deficiency in their ability to prevent bleeding. Currently, these patients must receive cumbersome bi-weekly IV infusions of clotting factor replacement therapy and may still bleed. Catalyst is developing a solution to give these patients a better and more convenient treatment particularly for inhibitor patients who have developed antibodies to their replacement therapy.
#hemophilia #catalystbio #subQ #biotech